---
title: "Imlifidase in Kidney transplantation in highly sensitized patients: Product information and disease description"
description: "Formulary evidence on Imlifidase in Kidney transplantation in highly sensitized patients: Product information and disease description. Covers Product description and Place of product in therapy. 77 evidence topics quoted from 59 sources."
canonical: "https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Imlifidase in Kidney transplantation in highly sensitized patients: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### FDA submission and designations

> “the submission of a Biologics License Application (BLA)”
> “FDA has granted Hansa Biopharma Fast Track and Orphan Drug Designation and Hansa has requested Priority Review”

Source: [Hansa Biopharma BLA submission announcement (2025)](https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-submits-bla-to-fda-for-imlifidase-in-desensitization-for-kidney-transplantation/)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Under review; BLA submitted December 2025

> “Lund, Sweden, 19 December 2025.”
> “today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imlifidase.”

Source: [Hansa Biopharma BLA submission announcement (2025)](https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-submits-bla-to-fda-for-imlifidase-in-desensitization-for-kidney-transplantation/)

<a id="topic-2.1.1-3"></a>

##### FDA acceptance

> “Hansa Biopharma’s Biologics License Application (BLA) for imlifidase accepted by the FDA”

Source: [Hansa Biopharma BLA acceptance announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda/)

<a id="topic-2.1.1-4"></a>

##### PDUFA action date

> “December 19, 2026”

Source: [Hansa Biopharma PDUFA action date announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/pdufa-action-date-for-hansa-biopharmas-imlifidase-bla-set-for-december-19-2026/)

<a id="topic-2.1.1-5"></a>

##### Launch: Anticipated in the first quarter of 2027

> “Imlifidase Potentially Available in Q1 2027*”
> “*Subject to FDA Approval”

Source: [Hansa Biopharma capital markets presentation (2026)](https://www.hansabiopharma.com/files/Presentations/2026/capital-markets-jun-25-2026--for-external-use.pdf)

<a id="topic-2.1.1-6"></a>

##### European authorization

> “Idefirix received a conditional marketing authorisation valid throughout the EU on 25 August 2020.”

Source: [European Medicines Agency Idefirix EPAR](https://www.ema.europa.eu/en/medicines/human/EPAR/idefirix)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Hansa Biopharma

> “Hansa Biopharma AB, (“Hansa” or “the Company”), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase has been accepted”

Source: [Hansa Biopharma BLA acceptance announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda/)

<a id="topic-2.1.2.1-2"></a>

###### Product identity

> “Idefirix contains the active substance imlifidase.”

Source: [European Medicines Agency Idefirix EPAR](https://www.ema.europa.eu/en/medicines/human/EPAR/idefirix)

Additional sources: [Al-Salama (2020)](https://pubmed.ncbi.nlm.nih.gov/33058042/)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Vial content

> “Each vial contains 11 mg imlifidase produced in Escherichia coli cells by recombinant DNA technology.”

Source: [Idefirix UK Summary of Product Characteristics](https://www.medicines.org.uk/emc/product/13155/smpc)

<a id="topic-2.1.2.2-2"></a>

###### Pharmaceutical form

> “Powder for concentrate for solution for infusion”

Source: [Swissmedic Idefirix risk management plan summary](https://www.swissmedic.ch/dam/swissmedic/de/dokumente/marktueberwachung/rmp/imlifidase_idefirix-rmp-summary.pdf.download.pdf/imlifidase_Idefirix_RMP-Summary.pdf)

<a id="topic-2.1.2.2-3"></a>

###### Material safety data sheet for the medicinal product

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### United States average sales price and wholesale acquisition cost

No evidence found.

<a id="topic-2.1.2.3-2"></a>

###### Irish economic assessment: wholesaler price and two-vial cost excluding VAT

| Cost input | Quoted amount |
| --- | --- |
| Wholesaler price per vial | “€148,080.77” |
| Two-vial cost | “€296,161.54” |

Source: [NCPE (2024)](https://www.ncpe.ie/wp-content/uploads/2024/11/Imlifidase-Technical-Summary-23041.pdf)

Additional sources: [NICE TA809 information about imlifidase (2022)](https://www.nice.org.uk/guidance/ta809/chapter/2-Information-about-imlifidase)

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Pharmacotherapeutic classification

> “Pharmacotherapeutic group: Immunosuppressants, selective immunosuppressants, ATC code: L04AA41.”

Source: [Idefirix UK Summary of Product Characteristics](https://www.medicines.org.uk/emc/product/13155/smpc)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### European indication

> “desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.”

Source: [Hansa Biopharma regulatory status page](https://www.hansabiopharma.com/our-science/regulatory-status/)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Mechanism of action

> “Imlifidase is an IgG-inactivating therapy based on a cysteine protease originating from Streptococcus pyogenes.”
> “cleaves IgG-antibodies and inhibits their activity within hours after administration.”

Source: [Hansa Biopharma imlifidase page](https://www.hansabiopharma.com/our-science/imlifidase/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Pharmacodynamics and immunogenicity: NCT02224820

> “<1% plasma IgG remaining within 48 hours”
> “Anti-IdeS antibodies developed 1 week after treatment, peaking at 2 weeks.”

Source: [Lorant et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6221156/)

<a id="topic-2.1.2.6.2-2"></a>

###### Phase 1 study in healthy subjects: NCT01802697

> “Twenty healthy subjects were given intravenous single ascending doses of IdeS.”
> “IgG reached nadir 6-24 hours after dosing and then slowly recovered.”

Source: [Winstedt et al. (2015)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0132011)

<a id="topic-2.1.2.6.2-3"></a>

###### Imlifidase-generated single-cleaved IgG

> “ScIgG has a significantly reduced capacity to mediate Fc-dependent effector functions.”

Source: [Bockermann et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9213077/)

<a id="topic-2.1.2.6.2-4"></a>

###### F(ab′)2 fragments and complement activation: in vitro study

> “F(ab′)2 fragments generated from anti-HLA antibodies after imlifidase cleavage had a biological impact on intact IgG binding, leading to reduced complement activation.”

Source: [Devriese et al. (2025)](https://onlinelibrary.wiley.com/doi/full/10.1111/tan.70502)

<a id="topic-2.1.2.6.2-5"></a>

###### Anti-IdeS antibodies in healthy humans

> “clinically significant levels of IdeS-neutralizing activity were found in only ~1% of the individuals tested.”

Source: [Hannachi et al. (2026)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1728855/full)

Additional sources: [Ge et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32732834/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Pharmacokinetics

> “Quoted elimination half life of imlifidase is 89 (60-238) hours.”

Source: [Phelan and Turner (2025)](https://edren.org/ren/handbook/transplant-handbook/immunosuppression-protocol/imlifidase-enabled-transplantation/)

<a id="topic-2.1.2.6.3-2"></a>

###### Product information: pharmacokinetic parameters

| Parameter | Quoted value |
| --- | --- |
| Mean maximum concentration after 0.25 mg/kg | “5.8 (4.2‑8.9) µg/mL” |
| Mean distribution half-life | “1.8 (0.6‑3.6) hours” |
| Mean elimination half-life | “89 (60‑238) hours” |
| Mean clearance | “1.8 (0.6‑7.9) mL/h/kg” |
| Mean distribution volume during elimination | “0.20 (0.06‑0.55) L/kg” |

Source: [Idefirix UK Summary of Product Characteristics](https://www.medicines.org.uk/emc/product/13155/smpc)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### Serious adverse reactions

> “The most common serious adverse reactions in clinical studies were pneumonia (5.6%) and sepsis (3.7%).”

Source: [Idefirix UK Summary of Product Characteristics](https://www.medicines.org.uk/emc/product/13155/smpc)

<a id="topic-2.1.2.7.1-2"></a>

###### Selected contraindications

> “Ongoing serious infection.”
> “Thrombotic thrombocytopenic purpura (TTP).”

Source: [Idefirix UK Summary of Product Characteristics](https://www.medicines.org.uk/emc/product/13155/smpc)

<a id="topic-2.1.2.7.1-3"></a>

###### Identified risks and infection prevention

> “Severe or serious infection”
> “Infusion-related reactions”
> “To minimise the risk of infections, all patients should receive treatment with antibiotics.”

Source: [Swissmedic Idefirix risk management plan summary](https://www.swissmedic.ch/dam/swissmedic/de/dokumente/marktueberwachung/rmp/imlifidase_idefirix-rmp-summary.pdf.download.pdf/imlifidase_Idefirix_RMP-Summary.pdf)

<a id="topic-2.1.2.7.1-4"></a>

###### Interference with alloantibody screening: case report

> “Following imlifidase treatment, alloantibody screening prior to blood transfusion returned a false-negative result”

Source: [Osmani et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1111/trf.18447)

<a id="topic-2.1.2.7.1-5"></a>

###### Interference with protein electrophoresis and immunofixation

> “In conclusion, imlifidase is a new exogenous substance that interferes with SPE, ISE and IFE in a new way.”

Source: [Davanzo et al. (2025)](https://d-nb.info/1366870824/34)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Hepatic impairment and pediatric populations

| Population | Quoted safety and efficacy information |
| --- | --- |
| Moderate or severe hepatic impairment | “have not been established. No data are available.” |
| Children and adolescents younger than 18 years | “No data are available.” |

Source: [Therapeutic Goods Administration Idefirix product information (2024)](https://www.tga.gov.au/sites/default/files/2024-05/auspar-idefirix-240509-pi.pdf)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Imlifidase

<a id="topic-2.1.2.9.1-1"></a>

###### Drug interactions

> “Avoid intravenous immunoglobulins within four weeks and other IgG-based biologics within two weeks before imlifidase because of potential enzyme neutralisation or loss of biologic effect.”

Source: [Transplantation Society of Australia and New Zealand (2026)](https://tsanz.com.au/storage/Guidelines/TSANZ_Guidelines-for-Imlifidase-Supported-Kidney-Transplantation-in-Australia_final-2.pdf)

<a id="topic-2.1.2.9.1-2"></a>

###### Neutralizing antibodies in intravenous immunoglobulin preparations

> “anti-IdeS IgG capable of neutralizing IdeS enzymatic activity in therapeutic preparations of pooled normal human IgG (IVIg).”

Source: [Hannachi et al. (2026)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1728855/full)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Imlifidase on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Potential impairment of alemtuzumab activity after imlifidase

> “Alemtuzumab may not be effective on Day 4 in some patients (as imlifidase may still be active).”

Source: [Phelan and Turner (2025)](https://edren.org/ren/handbook/transplant-handbook/immunosuppression-protocol/imlifidase-enabled-transplantation/)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Dose

> “The recommended dose is 0.25 mg/kg administered as a single dose preferably within 24 hours before transplantation.”

Source: [Therapeutic Goods Administration Idefirix product information (2024)](https://www.tga.gov.au/sites/default/files/2024-05/auspar-idefirix-240509-pi.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Route and infusion duration

> “intravenous use only”
> “15 minutes”

Source: [Therapeutic Goods Administration Idefirix product information (2024)](https://www.tga.gov.au/sites/default/files/2024-05/auspar-idefirix-240509-pi.pdf)

<a id="topic-2.1.2.10.2-2"></a>

###### Premedication

> “Pre-medication: IV chlorpheniramine 10mg and IV hydrocortisone 200mg to prevent infusion reactions.”

Source: [Phelan and Turner (2025)](https://edren.org/ren/handbook/transplant-handbook/immunosuppression-protocol/imlifidase-enabled-transplantation/)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Hospital restriction

> “Imlifidase is restricted to hospital use only.”

Source: [Therapeutic Goods Administration Idefirix product information (2024)](https://www.tga.gov.au/sites/default/files/2024-05/auspar-idefirix-240509-pi.pdf)

<a id="topic-2.1.2.11-2"></a>

###### European and MENA rights acquired by SERB

> “completed the acquisition of exclusive development and commercialization rights to Idefirix® (imlifidase)”

Source: [SERB Pharmaceuticals (2026)](https://serb.com/news/serb-pharmaceuticals-completes-acquisition-of-european-and-mena-rights-to-idefirix-imlifidase-from-hansa-biopharma/)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### French consensus protocol: accompanying immunosuppression

> “steroids, rATG, high dose IVIg, rituximab, tacrolimus and mycophenolic acid.”

Source: [Couzi et al. (2023)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2023.11244/full)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Imlifidase on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Welsh commissioning requirements for quality monitoring

> “The Provider must work to written quality standards and provide monitoring information to the lead commissioner.”

Source: [Welsh Kidney Network (2026)](https://jcc.nhs.wales/clinical-policies/welsh-kidney-network/imlifidase-desensitisation-treatment-option-for-adults-who-are-awaiting-a-kidney-transplant-from-a-deceased-donor-policy-position-statement-pps256-january-2026/)

<a id="topic-2.1.2.13-2"></a>

###### Demonstrated effect on quality-measure performance

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### ConfIdeS: randomized comparison of kidney function at 12 months

| Outcome | Imlifidase arm | Control arm |
| --- | --- | --- |
| Mean eGFR, mL/min/1.73 m² | “51.5” | “19.3” |

Source: [Hansa Biopharma ConfIdeS primary endpoint announcement (2025)](https://www.hansabiopharma.com/media/press-releases/2025/imlifidase-successfully-meets-primary-endpoint-in-pivotal-us-phase-3-confides-trial-in-kidney-transplantation/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Kidney failure

> “If your kidney function drops below 15 percent of normal, you are said to have kidney failure.”

Source: [National Institute of Diabetes and Digestive and Kidney Diseases](https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/what-is-kidney-failure)

<a id="topic-2.2.1.1-2"></a>

###### Sensitization risk factors

> “Sensitization usually occurs as a consequence of pregnancy, blood transfusions, tissue graft or previous transplantation.”

Source: [HRSA Organ Procurement and Transplantation Network](https://www.hrsa.gov/optn/policies-bylaws/public-comment/remove-cpra-99-100-form-highly-sensitized-kidney-candidates)

<a id="topic-2.2.1.1-3"></a>

###### HLA sensitization

> “their immune system makes antibodies against one or more HLA antigens or alleles in the donor pool.”

Source: [HRSA Organ Procurement and Transplantation Network](https://www.hrsa.gov/optn/policies-bylaws/public-comment/remove-cpra-99-100-form-highly-sensitized-kidney-candidates)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Kidney transplantation in highly sensitized patients

No evidence found.

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Kidney transplantation in highly sensitized patients

<a id="topic-2.2.1.2.2-1"></a>

###### Transplant-waiting-list population

> “Across the U.S. and Europe, highly sensitized patients comprise around 10-15% of the total of patients on transplant waiting lists.”

Source: [Hansa Biopharma ConfIdeS ATC 2026 plenary abstract announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-announces-confides-phase-3-abstract-selected-for-whats-hot-whats-new-plenary-at-atc-2026/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Transplant access and unmet need: background studies

> “we found 1597 additional sensitized (CPRA 50–<99.9%) candidates with meaningfully lower than average access to transplant”

Source: [Maldonado et al. (2023)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.14946)

> “Although the TR increased sharply for the CPRA 99.9%+ group with KAS, it remained markedly lower than the average despite national priority.”

Source: [Maldonado et al. (2021)](https://www.lidsen.com/journals/transplantation/transplantation-05-02-143)

<a id="topic-2.2.1.3-2"></a>

###### Waiting time and mortality risk

> “longer time waiting for a suitable donor relates to an increased mortality risk.”

Source: [Hansa Biopharma ConfIdeS ATC 2026 plenary abstract announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-announces-confides-phase-3-abstract-selected-for-whats-hot-whats-new-plenary-at-atc-2026/)

Additional sources: [Jackson et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32065704/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Antibody-mediated effector activity

> “Antibody-dependent cell-mediated cytotoxicity (ADCC) is an important pathway responsible for antibody-mediated rejection (AMR).”

Source: [Ge et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32732834/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### International Delphi consensus on imlifidase desensitization

> “crossmatch conversion from positive to negative in patients treated with imlifidase should be confirmed before transplantation”

Source: [Furian et al. (2025)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.13886/full)

Additional sources: [de Weerd et al. (2023)](https://journals.lww.com/transplantjournal/fulltext/2023/01000/re__imlifidase_generated_single_cleaved_igg_.35.aspx); [Guney et al. (2026)](https://www.sciencedirect.com/science/article/abs/pii/S0955470X26000169)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Fluid retention: manifestations of kidney failure

> “have swelling, usually in your legs, feet, or ankles”

Source: [National Institute of Diabetes and Digestive and Kidney Diseases](https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/what-is-kidney-failure)

<a id="topic-2.2.1.6-2"></a>

###### Fatigue and sleep disturbance: manifestations of kidney failure

> “feel tired during the day and have sleep problems at night”

Source: [National Institute of Diabetes and Digestive and Kidney Diseases](https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/what-is-kidney-failure)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Cardiovascular burden in kidney disease

> “Heart disease is the most common cause of death among people who have kidney disease.”

Source: [National Institute of Diabetes and Digestive and Kidney Diseases (2016)](https://www.niddk.nih.gov/health-information/kidney-disease/heart-disease)

<a id="topic-2.2.1.7-2"></a>

###### Mineral and bone disorder in chronic kidney disease

> “bones gradually become thin and weak.”
> “bones and joints may begin to feel painful.”

Source: [National Institute of Diabetes and Digestive and Kidney Diseases (2021)](https://www.niddk.nih.gov/health-information/kidney-disease/mineral-bone-disorder)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Kidney transplantation in highly sensitized patients

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Humanistic burden

> “Kidney failure will change your day-to-day activities”

Source: [National Institute of Diabetes and Digestive and Kidney Diseases](https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/what-is-kidney-failure)

<a id="topic-2.2.1.8.1-2"></a>

###### Irish economic model: utility-data limitation

> “Another limitation is that utility data specific to highly sensitised ESRD patients were not available.”

Source: [Lauzon et al. (2025)](https://www.ispor.org/docs/default-source/cti-meeting-21305-documents/a9048821-885f-4555-a75b-7bf3be5989e4.pdf)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### In-center hemodialysis: treatment frequency and duration

> “usually three times per week”
> “Each dialysis session lasts about 4 hours.”

Source: [National Institute of Diabetes and Digestive and Kidney Diseases (2018)](https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/hemodialysis)

<a id="topic-2.2.1.8.2-2"></a>

###### Irish economic model: probabilistic sensitivity analysis

> “dominant versus SoC in 94.5% of model simulations”

Source: [Lauzon et al. (2025)](https://www.ispor.org/docs/default-source/cti-meeting-21305-documents/a9048821-885f-4555-a75b-7bf3be5989e4.pdf)

Additional sources: [Vo et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23511212/); [Axelrod et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12404663/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Kidney transplantation in highly sensitized patients on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Background evidence: caregivers of children with chronic kidney disease in Egypt

> “250 caregivers of children with CKD”
> “Although the majority (87.2%) of caregivers suffered different degrees of financial hardship”

Source: [Darwish et al. (2020)](https://link.springer.com/article/10.1186/s42506-020-00058-7)

<a id="topic-2.2.1.8.3-2"></a>

###### Costs borne by families of highly sensitized adult transplant candidates

No evidence found.

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### French selection pathway: cost implications of diluted-serum HLA testing

> “This recommendation increases significantly the cost of HLA testing”

Source: [Couzi et al. (2023)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2023.11244/full)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Compatible Donor Allocation and Acceptable Mismatch Programs

<a id="topic-2.2.2.1.1-1"></a>

###### European guidance on acceptable mismatch programs

> “The Eurotransplant Acceptable Mismatch program should be extended.”

Source: [Mamode et al. (2022)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2022.10511/full)

<a id="topic-2.2.2.1.1-2"></a>

###### Belgian consensus: Acceptable Mismatch program

> “For patients who remain in the AM program for ≥3 y without undergoing transplantation, an additional prioritization strategy has been implemented.”

Source: [Kuypers et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40320582/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Kidney Paired Exchange

<a id="topic-2.2.2.1.2-1"></a>

###### European Society for Organ Transplantation guideline

> “highly sensitized patients should not be left on a KEP list indefinitely if the option of a direct incompatible transplant exists.”

Source: [Mamode et al. (2022)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2022.10511/full)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Plasma Exchange and Immunoadsorption

<a id="topic-2.2.2.1.3-1"></a>

###### Existing desensitization approaches

> “Desensitisation is currently based on protocols using apheresis and/or medicinal products used off-label.”

Source: [Haute Autorité de Santé (2022)](https://www.has-sante.fr/jcms/p_3332338/en/idefirix-imlifidase)

<a id="topic-2.2.2.1.3-2"></a>

###### Guideline-supported antibody removal with adjunctive therapy

> “plasma exchange or immunoadsorption, supplemented with IViG and/or anti-CD20 antibody.”

Source: [Mamode et al. (2022)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2022.10511/full)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Intravenous Immunoglobulin

<a id="topic-2.2.2.1.4-1"></a>

###### European consensus: first-line desensitization

> “PEX and IVIg should be part of the first line desensitization strategy”

Source: [Furian et al. (2024)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12475/full)

Additional sources: [Chandramohan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39202740/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 B-cell-depleting Antibodies

<a id="topic-2.2.2.1.5-1"></a>

###### European consensus: adjunctive prevention of antibody rebound

> “rituximab might be considered as an adjunct to prevent antibody rebound”

Source: [Furian et al. (2024)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12475/full)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 IgG-cleaving Enzyme Therapy

<a id="topic-2.2.2.1.6-1"></a>

###### French consensus guidelines: patient selection

> “cPRA ≥ 98%, ≤ 65-year of age, ≥ 3 years on the waiting list, and a low risk of biopsy-related complications.”

Source: [Couzi et al. (2023)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2023.11244/full)

<a id="topic-2.2.2.1.6-2"></a>

###### European Delphi consensus on sensitized kidney-transplant recipients

> “imlifidase might be considered for deceased kidney transplantation in selected patients for whom there are no other treatment options”

Source: [Furian et al. (2024)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12475/full)

Additional sources: [Mancebo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40209457/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Induction and Maintenance Immunosuppression

<a id="topic-2.2.2.1.7-1"></a>

###### Selected agents in the French imlifidase-enabled transplantation protocol

| Treatment role | Quoted agent |
| --- | --- |
| T-cell-depleting induction | “rATG” |
| Calcineurin inhibition | “tacrolimus” |
| Antimetabolite maintenance | “mycophenolic acid” |

Source: [Couzi et al. (2023)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2023.11244/full)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Maintenance Dialysis

<a id="topic-2.2.2.1.8-1"></a>

###### Dialysis modalities for kidney failure

> “hemodialysis”
> “peritoneal dialysis”

Source: [National Institute of Diabetes and Digestive and Kidney Diseases](https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/what-is-kidney-failure)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

###### Summary

Existing desensitization approaches include apheresis and off-label medicines. These regimens may require repeated treatment over weeks or months and may not reduce antibodies sufficiently to permit transplantation. Compatible allocation and kidney exchange do not resolve access for every highly sensitized candidate; United States analyses identified persistent access limitations even after allocation priority. European guidance advises against leaving highly sensitized candidates on a kidney exchange list indefinitely when an incompatible transplant is a feasible option. Some practical recommendations for imlifidase-enabled transplantation remain based on evidence that expert authors describe as lacking high-level scientific support.

Source: [Haute Autorité de Santé (2022)](https://www.has-sante.fr/jcms/p_3332338/en/idefirix-imlifidase); [Maldonado et al. (2023)](https://onlinelibrary.wiley.com/doi/full/10.1111/ctr.14946); [Maldonado et al. (2021)](https://www.lidsen.com/journals/transplantation/transplantation-05-02-143); [Mamode et al. (2022)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2022.10511/full); [Reuter et al. (2026a)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1846251/full)

<a id="topic-2.2.2.1.9-2"></a>

###### Conventional desensitization: treatment duration and incomplete response

> “repeated doses for several weeks or months prior to transplantation”
> “It does not always enable a sufficient reduction in antibodies to allow transplantation”

Source: [Haute Autorité de Santé (2022)](https://www.has-sante.fr/jcms/p_3332338/en/idefirix-imlifidase)

<a id="topic-2.2.2.1.9-3"></a>

###### German expert consensus: evidence limitations

> “lack high-level scientific evidence”

Source: [Reuter et al. (2026a)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1846251/full)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

The cited European indication concerns highly sensitized adults with a positive crossmatch against an available deceased donor, and European consensus considers imlifidase for selected candidates without other treatment options. The French consensus specifies cPRA of at least 98%, age no greater than 65 years, at least three years on the waiting list, and low biopsy-complication risk; these are consensus selection criteria rather than a universal label restriction. Administration is restricted to hospital use. Crossmatch conversion must be confirmed before transplantation. The French protocol combines imlifidase with additional immunosuppression, and German consensus recommends considering an early protocol biopsy between days 7 and 10 when clinically feasible.

Source: [Hansa Biopharma regulatory status page](https://www.hansabiopharma.com/our-science/regulatory-status/); [Furian et al. (2024)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.12475/full); [Couzi et al. (2023)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2023.11244/full); [Therapeutic Goods Administration Idefirix product information (2024)](https://www.tga.gov.au/sites/default/files/2024-05/auspar-idefirix-240509-pi.pdf); [Furian et al. (2025)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.13886/full); [Reuter et al. (2026a)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1846251/full)

Additional sources: [Huang et al. (2022)](https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.16828); [Kanbay et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10949912/); [Krishnan et al. (2024)](https://indianjnephrol.org/imlifidase-is-it-the-magic-wand-in-renal-transplantation/); [Reuter et al. (2026b)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1868642/full); [Lonze (2021)](https://pubmed.ncbi.nlm.nih.gov/33180664/); [Jackson (2026)](https://pubmed.ncbi.nlm.nih.gov/41631379/); [Jaffe et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40320584/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Baseline donor-specific antibodies and early rejection risk

> “Patients with very high levels of DSA before transplantation are more likely to experience early AMR that requires intervention.”

Source: [European Medicines Agency Idefirix product information (2026)](https://www.ema.europa.eu/en/documents/product-information/idefirix-epar-product-information_en.pdf)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### German expert consensus: biopsy surveillance

> “an early protocol biopsy should be considered between days 7 and 10 after transplantation, where clinically feasible”

Source: [Reuter et al. (2026a)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1846251/full)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

<a id="topic-2.2.2.5-1"></a>

###### Sponsor-reported agreement on follow-up in the proposed accelerated approval pathway

> “long-term follow-up agreed with the FDA as part of the accelerated approval pathway”

Source: [Hansa Biopharma BLA acceptance announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda/)

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

<a id="topic-2.2.2.6-1"></a>

###### European conditional authorization: long-term effectiveness follow-up

> “The company that markets Idefirix will provide results of a long-term study of Idefirix to confirm its effectiveness.”

Source: [European Medicines Agency Idefirix EPAR](https://www.ema.europa.eu/en/medicines/human/EPAR/idefirix)

<a id="topic-2.2.2.6-2"></a>

###### Company-reported completion of the post-authorization efficacy study obligation

> “the post-authorization obligation has now been fulfilled”

Source: [SERB Pharmaceuticals (2026)](https://serb.com/news/serb-pharmaceuticals-completes-acquisition-of-european-and-mena-rights-to-idefirix-imlifidase-from-hansa-biopharma/)

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### European post-authorization efficacy study: one-year outcomes

> “The 1-year graft failure-free survival was 90%”
> “graft survival was 92%, and patient survival was 98%.”

Source: [Hansa Biopharma European post-authorization study results announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-reports-positive-efficacy-and-safety-results-from-idefirix-european-post-authorization-study-in-kidney-transplantation/)

## Related pages
- [Imlifidase: Kidney transplantation in highly sensitized patients](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: Terms and abbreviations](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/terms-and-abbreviations.md)
- [Imlifidase: Kidney transplantation in highly sensitized patients](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/executive-summary) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/executive-summary.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: Clinical evidence](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/clinical-evidence.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: Economic information and modeling report](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/economics) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/economics.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: References](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/references) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/references.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: prevalence by geography](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/prevalence) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/prevalence.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/cost-effectiveness-analyses.md)
